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Mutation in leucine-rich repeat kinase 2 (LRRK2) is a com-
mon cause of familial Parkinson’s disease (PD). Recently, we
showed that a disease-associated mutation R1441H rendered
the GTPase domain of LRRK2 catalytically less active and
thereby trapping it in a more persistently “on” conformation.
However, themechanism involved and characteristics of this on
conformation remained unknown. Here, we report that the Ras
of complex protein (ROC) domain of LRRK2 exists in a dynamic
dimer–monomer equilibrium that is oppositely driven by GDP
and GTP binding. We also observed that the PD-associated
mutations at residue 1441 impair this dynamic and shift the
conformation of ROC to aGTP-bound–likemonomeric confor-
mation. Moreover, we show that residue Arg-1441 is critical for
regulating the conformational dynamics of ROC. In summary,
our results reveal that the PD-associated substitutions at Arg-
1441 of LRRK2 alter monomer–dimer dynamics and thereby
trap its GTPase domain in an activated state.
Age-associated neurodegeneration is one of themost desper-
ate and challenging public health crises due to the rapidly aging
population and the lack of effective treatments (1). Fortunately,
discoveries of precise mutations in disease-associated genes in
recent decades have provided new venues for developingmech-
anism-based therapeutic strategies. One of these genes is called
leucine-rich repeat kinase 2 (LRRK2)3, mutations in which are
common causes of Parkinson’s disease (PD) (2–6). LRRK2 is a
large multidomain protein (2,527 amino acids) consisting of
seven putative domains (3), including a Ras-like GTPase
domain called “Ras of complex proteins” (ROC) followed by a
domain called C-terminal of ROC (COR), then a kinase domain
(Kin). It remains unclear as to how perturbations of LRRK2
activities result in disease. However, the most common muta-
tion in LRRK2-associated PD, G2019S in the kinase domain,
shows higher kinase activity than that of the wildtype (WT);
therefore, its over-activation might be associated with disease
pathogenesis (7).
The tandemROC-COR-Kin arrangement suggests that their
activities might be coupled such that the GTPase activity of
ROCmight modulate the kinase activity of Kin. Indeed, several
studies have shown that GTP binding to the ROC domain reg-
ulates the activity of the Kin domain (8, 9) and inhibition of the
ROC domain affects the activity of the Kin domain (10). More-
over, PD-associated mutations in the ROC domain (R1441C)
have been shown to have higher kinase activity (11), suggesting
that mutations in the ROC domain might also up-regulate
kinase activity. We previously showed that the Parkinson’s dis-
ease-associated mutation R1441H locks the ROC domain in a
prolonged activated state (12) and a recent report showed that a
homologue of LRRK2, CtRoco, undergoes dimer–monomer
transition upon GTP binding (13), which together suggest that
perturbations in dimer–monomer dynamics might be the key
factor leading to the reduction in GTPase activity observed in
the PD-associated mutations at Arg-1441.
Here, we show that all the disease-associated mutations at
Arg-1441 we examined (R1441H/R1441G/R1441C) showed
decreased GTPase activity and a complete loss of monomer–
dimer conformational dynamics. These data, taken together
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with prior reports, suggest that the mutations at Arg-1441
impair monomer–dimer dynamics leading to trapping the
GTPase domain of LRRK2 in a more persistently “on” state.
Results and discussion
Arginine 1441 is uniquely essential for the GTPase activity of
ROC
A detailed understanding of LRRK2 has been hampered by a
lack of protein samples amenable for quantitative biochemical
and biophysical studies. As such, most of the detailed insights
into the structure and function of LRRK2 have been gleaned
from the observations of the homologous proteins. We have
recently created a stably-folded G-domain construct of LRRK2
consisting of residues 1329–1520 (Fig. 1) thatwe calledROCext,
which enabled us to study quantitatively the GTPase activity of
WT ROCext and the R1441H mutant (12). To further under-
stand the critical effects of the disease-associated mutations
and theirmechanisms leading to the biochemical perturbations
that we and others have observed (12, 14–16), we have created
stably-folded ROCext constructs harboring the disease-associ-
ated mutations R1441G/R1441C (in addition to the R1441H,
which we have previously described), and artificial mutants
R1441K/R1441Y for detailed biochemical investigations.
We first measured the GTP hydrolysis activities of the
R1441H, R1441G, and R1441C constructs and observed that
the specific GTPase activity (pmol mg1 min1) was 9.0 0.8,
12.6  0.8, and 12.9  0.8, respectively, which are 4-fold
lower than that of the WT (48.6  0.8) (Fig. 2a). We found it
notable that despite having very different side chain properties,
all the mutants showed a similar reduction in activity, which
suggests that the arginine residue at position 1441 might be
specifically essential for the activity of ROCext. To test this, we
made an artificial mutant substituting arginine 1441 for lysine
and measured its GTPase activity. Similarly, we observed that
the GTPase activity of the R1441Kmutant (SA 10.5 2.5) to
be about 4-fold lower than that of theWT (Fig. 2a). These data
further supports the notion that arginine at position 1441 is
uniquely important for ROCext activity; thus, understanding its
role would provide insights into the mechanism of this atypical
G-domain and its role in disease pathogenesis.
GTPase activity and thermostability
Wereported previously that the R1441Hmutant has a higher
affinity for GTP compared with that of WT, which we sug-
gested might be responsible, in part, for the aberrant activity of
LRRK2 (12). Todeterminewhether or not this is a general prop-
erty of mutations at Arg-1441, we measured the affinity of the
other mutants, R1441G and R1441C, for GDP and GTP using a
fluorescence polarization assay we previously described (12).
We reconfirmed that the R1441Hmutant has higher affinity for
GTP (Kd 3.0 0.4M) than that ofWT (Kd 4.1 0.3M);
however, they are not replicated in the R1441G and R1441C
mutants, which have similar GTP affinities (Kd 4.5 0.7 and
4.9  0.8 M, respectively) to the WT. Similarly, there are no
consistent trends for GDP affinity, where the R1441C mutant
has lower affinity for GDP (Kd 2.5 0.4 M) compared with
that of WT (Kd  1.2  0.1 M); whereas the R1441G (Kd 
1.8  0.3 M) and R1441H (Kd  1.9  0.3 M) mutants bind
GDP with affinities comparable with the WT (Fig. 2b). These
data indicate that the higher affinity for GTP observed in the
R1441Hmutant is not a commonly shared property among the
disease-associated mutations at position 1441; thus, it is prob-
ably not a key feature responsible for the reduction in GTPase
activity observed in the mutants.
Continuing our search for the fundamental properties that
rendered the Arg-1441 mutants less active, we measured the
thermal stability of each construct using a thermofluor-based
protein denaturation assay (17). We observed that the R1441H
ROCext mutant is as thermally stable as theWT with a melting
temperatures (Tm) of 54.3 0.1 and 54.3 0.1 °C, respectively
(Fig. 2c); whereas the Tm for the R1441G (Tm 50.5 0.1 °C)
and R1441C (Tm 51.5 0.1 °C)mutants are about 3 °C lower
than that of the WT (Fig. 2d). However, the GTPase activity
of the R1441Hmutant (despite having a higherTm) is similar to
that of R1441C and R1441G, thus it is unlikely that the lowered
thermal stability of themutants is responsible for the reduction
in GTPase activity mentioned above.
The PD-associatedmutations at residue 1441 disrupt dimer
formation
We next examined whether the mutations at position 1441
cause structural perturbation by using CD spectroscopy. We
found no significant differences in the CD spectra of the
mutants compared with that of the WT, indicating that the
mutations have no significant impact to the secondary struc-
ture of ROCext (Fig. 3a).
Previously we reported that WT ROCext existed in solution
in amonomer–dimer equilibrium (12), whichwas also recently
described for a LRRK2 homolog CtRoco, where the authors
suggested that the disease-associated mutations in the ROC
domain might disrupt the dimer–monomer dynamics (13). To
investigate the effects of PD-associated mutations on the
dimerization of ROC, we used multiangle light scattering cou-
Figure1. TheROCconstructsof LRRK2under investigation.a, a schematic
depiction of LRRK2 showing the boundaries of ROCext with respect to the
other domains, and the sites of PD-associated mutations studied. b, SDS-
PAGE of purified ROCext carrying the PD-associated mutations R1441H (H),
R1441G (G), and R1441C (C), and a synthetic mutant R1441K (K).
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pled to size-exclusion chromatography (SEC-MALS). We
found that all the mutants (R1441G/R1441C/R1441H) oc-
curred as only monomers (Fig. 3b). This result might suggest
that the monomeric form of ROC might be catalytically inac-
tive. However, in a previous study, we showed that the mono-
meric form of ROC is catalytically active.Moreover, we showed
that the addition of GTP to the GTPase reaction renders ROC
conversion fromdimer tomonomer. Therefore, it ismore likely
that the dimer–monomer inter-conversion or cycling is essen-
tial for GTP hydrolysis as recently suggested for CtRoco (13).
Conformational dynamics is essential for GTPase activity
Because all the disease-associated mutations at residue Arg-
1441 abolished ROCext dimerization, we investigated whether
or not position 1441 is critical for regulating the dimer–mono-
mer dynamics. Through systematic substitution mutations at
position 1441, we found that a ROCext containing a tyrosine
residue at 1441 forms a constitutive dimer with no observable
monomers (Fig. 4a). Interestingly, we found that the R1441Y
dimer is catalytically inactive (Fig. 4b). A similar observation
was recently made in a ROC homolog CtRoco (13), where a
constitutively dimeric mutant showed reduced GTPase activ-
ity. Taken together, our data suggest that the conformational
dynamics that occur in the monomer–dimer transition is
essential for theGTPase activity of LRRK2 and that the disease-
associated mutations at Arg-1441 disrupt this activity through
interfering with the dimer-monomer dynamics.
The remarkable similarities between LRRK2 ROCext and
CtRoco in their dimer–monomer dynamics suggests that their
mechanism of actions might be conserved. However, a critical
difference between CtRoco and our LRRK ROCext is that
CtRoco dimerization is driven by interactions in its COR
domain (13, 18), whereas our LRRK2 ROCext construct readily
forms dimers in the absence of the COR domain. This result
suggests that the dimerization mechanism of LRRK2 ROC
might be different from that of CtRoco. Indeed, as mentioned
Figure 2. Biochemical properties of PD-associatedmutations in theROCdomainof LRRK2 comparedwith theWT. a, GTPase activity, phosphate release
against time, of WT (black line) ROCext and various mutants R1441C (orange), R1441G (gray), R1441H (blue), and R1441K (green). b, fluorescence polarization-
based GDP binding assay ofWT ROCext (black) and the PD-associatedmutants R1441C/R1441G/R1441H (orange, gray, and blue, respectively). Affinity is shown
in parentheses. c, fluorescence polarization-based GTP-binding assay of WT ROCext (black) and the PD-associated mutants R1441C/R1441G/R1441H (orange,
gray, and blue, respectively). Affinity is shown in parentheses. d, fluorescence-based thermal denaturation assay of ROCext (black), R1441C (orange), R1441G
(gray), and R1441H (blue). Melting temperature of shown in parentheses.
Figure 3. Conformations of PD-associatedmutations in the ROC domain of LRRK2 compared with theWT. a, CD spectrometry of WT (black line) ROCext
and various mutants R1441C (orange), R1441G (gray), R1441H (blue). b, SEC-MALS of WT ROCext dimer (solid black line), WT monomer (dotted black line) along
with the PD-associated mutants R1441C/R1441G/R1441H (orange, gray, and blue, respectively).
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above, the R1441Ymutation in ROCext locks it in a constitutive
homodimeric state; however, the equivalent WT position in
CtRoco, residue 558, is natively tyrosine. Moreover, mutations
in CtRoco at Tyr-558 mimicking the LRRK2 R1441G/R1441C/
R1441H did not affect its dimerization, whereas these muta-
tions in LRRK2 ROCext abolished dimer formation as shown
above. These similarities and differences between CtRoco and
LRRK2 suggest that the subtle variability in the mechanisms of
action observed in the typical Ras and Rab families of GTPases
might also occur in the Roco family of GTPases (19).
PD-associatedmutations abolish the guanine nucleotide-
dependent dimer–monomer interconversions
We and others have previously shown that incubating
dimeric ROC with GTP renders it monomeric (12, 20), which
suggest that guanine nucleotides might regulate the dynamics
of ROC oligomerization. However, in our previous investiga-
tion, we observed that both GTP and GDP were equally effec-
tive for converting dimeric ROC to its monomeric conforma-
tion (12). Through further investigations, we observed that the
EDTA used in the nucleotide exchange itself was sufficient to
convert all the dimers into monomers. Based on this, we
hypothesized that the monomerization effects of EDTA might
have masked the potentially differential effects of GTP and
GDP. To investigate this, we incubated ROCext (93% dimers)
with varying concentrations ofGDPorGTPwithout EDTAand
analyzed their proportions of dimers andmonomers using size-
exclusion chromatography. As expected, we observed a GTP
concentration-dependent conversion of dimeric ROCext to
monomerswithanequilibriumproportionofdimersandmono-
mers at 5 mM GTP to be 15 and 85%, respectively (Fig. 5a). In
contrast, GDP caused a significantly smaller shift in the dimer–
monomer equilibrium with a ratio of dimer:monomer at
71:29% in 5 mM GDP (Fig. 5b). These results indicate that GTP
drives ROC dimers toward monomers and, reciprocally, GDP
shifts the equilibrium toward the dimeric conformation. To
investigate this, we developed a method to detect a dynamic
conversion from dimer to monomer and then back to dimer in
the same protein sample. We did so by first starting with a
protein sample consisting ofmostly the dimeric formof ROCext
(85%), then we incubated it with GTP, which converts all the
dimers to monomers, and then followed by exchanging it with
GDP. We analyzed the dimeric state of the protein sample at
eachstepand foundthatdimericROCextdissociated intomono-
mers upon GTP binding and then about 18% reassembled into
dimers upon exchanging for GDP, but none converted to
dimers when GTP was added instead at this stage (Fig. 5c). In
contrast, the PD-associated mutation R1441G entirely abol-
ished the dimer–monomer dynamics, where it was trapped
in a monomeric conformation similar to the GTP-bound sam-
ples (Fig. 5d). These results unambiguously demonstrate a
reversible dynamic interconversion between dimers andmono-
mers that is mediated by GDP and GTP binding, respectively,
and that the PD-associated mutation abolishes this dynamic
process.
Conformational changes in ROC regulate LRRK2 subcellular
localization
To investigate the potential significance of the observed
dimer–monomer dynamics of ROC in the context of the full-
length LRRK2 in live cells, we examined the subcellular local-
izationof LRRK2carrying themutations that gave rise tomono-
meric and dimeric ROCext. We used our previously described
method to characterize interactions of LRRK2 with a binding
partner RAB29 (21) in HEK293FT cells. Under normal condi-
tions LRRK2 is localized to the cytosol, butwhen co-transfected
with RAB29 it re-localizes in clusters that overlap with the
trans-Golgi network. Upon over-expression of the mutants
with RAB29 in HEK293FT cells, we observed a significant
increase in LRRK2 re-localization to the trans-Golgi network
with all the Arg-1441 mutations compared with WT (Fig. 6).
Although the biological function of LRRK2 and its normal sub-
cellular localization are still unclear, our results clearly demon-
strate differential effects in subcellular localization between the
different mutations that are shown dimeric and monomeric in
our in vitro assays. Taken together, the results suggest that Arg-
1441 is critical for the conformational dynamics of ROC, which
modulates the activity and potentially the subcellular localiza-
tion of LRRK2.
Conclusion
Detailed investigations of LRRK2 has been stymied by a lack
of protein samples in the quality and quantity required for
quantitative studies. Recently, we reported the construction of
a ROCdomain and amethod to obtain it in a form amenable for
quantitative studies, which showed that disease-associated
mutation R1441H rendered it catalytically less active and
thereby, trapping it more persistently on conformation,
although we were unable to precisely define the “on conforma-
tion” at the time (12).
Figure 4. Oligomeric states andGTPase activity of R1441Y. a, size-exclusion chromatography of theWT dimer (solid black line), WTmonomer (dotted black
line), and theR1441Ymutant (green line).b, GTPase activity, phosphate release against time, of theR1441Ymutant (green) comparedwith that of theWT (black).
Mutations in ROC of LRRK2 impair conformational dynamics
5910 J. Biol. Chem. (2019) 294(15) 5907–5913
Here, in this report, we showed that the other disease-asso-
ciated mutations, R1441G and R1441C, also perturb the
GTPase activity of ROC, as well as abolishing their ability to
form dimers. This revealed that a single substitution mutation
at residue 1441 is sufficient to cause a significant conforma-
tional change in the ROC domain. We further showed that the
GDP-bound form of ROC exists in an equilibrium of dimers
and monomers, but favoring the dimeric conformation in a
ratio of about 7:3; however, upon binding GTP, the ratio is
shifted to 100% monomers. This indicated that GDP and GTP
might regulate a cycle of dimer–monomer conformational
dynamics in the ROC domain of LRRK2. Indeed, we were able
to demonstrate in the same protein sample that ROCext dimers
convert to monomers upon GTP binding and then cycled back
to the dimeric form upon binding to GDP. This result clearly
shows that the ROCext dimer–monomer conformational
change is in a dynamic equilibrium that is oppositely driven
by GDP and GTP binding, and that the disease-associated
mutations at residue 1441 impair this dynamic and shift the
equilibrium 100% to the GTP-bound-like monomeric con-
formation (Fig. 7). Moreover, the results presented herein
revealed that arginine 1441, whose mutation is associated
with PD, is critical for regulating the conformational dynam-
ics of ROC. We have recently described another PD-associ-
Figure 5. Nucleotide-dependent dimer–monomer equilibriumof ROC. a, size-exclusion chromatography of theWTROCext (solid black line) incubatedwith
2.5 mM GTP (orange dashed line) and 5.0 mM GTP (red dashed line). b, the same experiment as a, but with 2.5 mM GDP (light green dashed line) and 5.0 mM GDP
(green dashed line). c, dimer–monomer interconversion experiment showing that the same protein sample converting frommostly dimers (solid black line) to
nearly completely monomers upon binding excess GTP (dashed black line) and then reverts back to forming some dimers upon binding to GDP (green dashed
line), but the same treatment with GTP did not produce any dimers (red dashed line). d, the same experiment as c for the ROCext carrying the PD-associated
mutation R1441G, showing a complete loss of nucleotide-dependent dimer–monomer interconversion.
Figure6. Effects of PD-associatedmutationsonLRRK2.a, cell-based subcellular localization assay showing that thedisease-associatedmutations (R1441H/
R1441C/R1441G) that perturbedROCdimerization cause accumulation of full-length LRRK2 at the trans-Golgi network. The symbols ** and *** denotep values
0.001 to 0.01 and 0.0001 to 0.001, respectively. b, representative images of the HEK293FT cells collected in the trans-Golgi localization assay shown in a. The 50
m scale shown in the bottom right panel is representative of all other panels in the figure.
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ated mutation in ROC, N1437H, which also caused pertur-
bation in its dimer–monomer dynamics (22), thus this might
be a common effect of disease-associated mutations in the
GTPase domain of LRRK2.
Experimental procedures
Protein expression and purification
An extended GTPase domain of LRRK2 consisting of resi-
dues 1329–1520 (ROCext) was subcloned into a pETDuet-1
vector (Novagen, Darmstadt, Germany) using PCR cloning
techniques. The resulting protein consisting of an N-terminal
hexahistidine tag was expressed from Rosetta2 (DE3) Esche-
richia coli (Novagen) by inducing with 0.5 mM isopropyl -D-
thiogalactopyranoside for 16 h at 20 °C. Cells were harvested by
centrifugation and lysed by sonication in a buffer containing 30
mM HEPES (pH 7.4), 250 mM NaCl, 10 mM MgCl2, 10 mM gly-
cine, 20mM imidazole, 10MGDP, and 10% (v/v) glycerol. Cell
debris was cleared by ultracentrifugation at 14,000 g (35,000
rpm, Beckman 45 Ti rotor). The supernatant was incubated
with nickel-nitrilotriacetic acid-agarose (Qiagen, Hilden, Ger-
many) for 2 h at 4 °C, then washed with lysis buffer (detailed
above) and eluted with buffer containing 30 mM HEPES (pH
7.4), 250 mM NaCl, 10 mM MgCl2, 10 mM glycine, 300 mM im-
idazole, 1mMDTT, 10MGDP, and 10% glycerol. The purified
proteinwas then “polished” by passing through a size-exclusion
column (Superdex 200, GE Healthcare) in buffer containing 30
mM HEPES (pH 7.4), 150 mM NaCl, 10 mM MgCl2, 10 mM gly-
cine, 1 mM DTT, and 10% glycerol. The purified protein was
then concentrated to 15 mg/ml, flash frozen in liquid nitro-
gen, and stored at80 °C.
SEC-MALS
To determine the absolute molecular weight of Rocext in
solution, we used multiple angle light scattering. Our experi-
mental setup includes an AKTA FPLC (GE Healthcare Biosci-
ences) with a silica-based size exclusion chromatography col-
umn (WTC-030S5, Wyatt Technology Corporation, Santa
Barbara, CA) as liquid chromatography unit. Down from the
liquid chromatography units is a refractive index detector
(Optilab T-rEX, Wyatt Technology) followed by a multiple
light scattering detector (Dawn HeleosII, Wyatt Technology)
for determining protein concentration andparticle size, respec-
tively. Each sample injection consisted of 1 mg of purified
ROCext in buffer containing 30 mM HEPES (pH 7.4), 0.15 M
NaCl, 10 mM MgCl2, 10 mM glycine, 1 mM DTT, and 10% glyc-
erol. The flow ratewas set at 0.4ml/min and datawere collected
in a 1-s interval. Data processing and analysis were performed
using the ASTRA software (Wyatt Technology).
Dimer–monomer inter-conversion assay
To determine the effect of GDP/GTP cycles on the dynamic
oligomeric states, we incubated purified ROCext with GDP or
GTP in buffer containing 30 mMHEPES (pH 7.4), 0.15 M NaCl,
10 mM MgCl2, 10 mM glycine, 1 mM DTT, and 10% glycerol.
This incubation was done without addition of EDTA. To test
the dimeric to monomeric conversion, the dimeric protein
samples (15mg/ml, 0.6mM) were incubated in room temper-
aturewith 16mMof eitherGDPorGTP (25 to Roc) for 6 h. To
test themonomeric to dimeric conversion, themonomeric pro-
tein samples were first obtained by GTP incubation and desalt-
ing purification (Zeba spin desalting column, Thermo Fisher).
Themonomeric samples were then incubatedwith 16mMGDP
or GTP for 6 h. The ratios of monomeric and dimeric forms of
the incubated samples were then determined by size exclusion
chromatography (Superdex 75, GE Healthcare).
Circular dichroism spectroscopy
CD spectra were collected on a Biologic Science Instruments
MOS450 AF/CD spectrometer with the slit width of 1.0 mm and
data acquisition of 1.0 s. The protein samples with concentrations
ranging from0.46 to 0.86mg/ml (based on absorbance at 280 nm)
were dissolved in the buffer containing 10 mM Tris-HCl (pH 7.4),
150 mM NaCl, 5 mM MgCl2, 1 mM DTT, and 5% glycerol. Data
were analyzed with Dichroweb and plotted with Prism 7.
Fluorescence polarization nucleotide-binding assay
To estimate the binding affinity of guanine nucleotides
BODIPY-FL-GTPS (100 nM) or BODIPY-FL-GDP (150 nM)
(Molecular Probes) were titrated with ROCext (starting at 0.1
M) until saturation was reached (15 and 10 M, respec-
tively). Fluorescence polarization signals were read using an
EnVison 2102Multilabel Plate Reader (PerkinElmer Life Sci-
ences) with excitation at 485 nm and emission at 535 nm.
Experiments were performed at 25 °C in buffer containing 30
mM HEPES (pH 7.4), 150 mM NaCl, 10 mM MgCl2, 10 mM
glycine, 4 mM EDTA, 1 mM DTT, 10% glycerol. Data were
analyzed using Prism 7 (GraphPad Software).
GTPase activity assay
GTPase activity of ROCext was assessed by using the Enz-
check assay kit (Invitrogen) according to the manufacturer’s
instructions. Briefly, Rocext (30 M) was incubated with 2 mM
GTP in buffer containing 30mMHEPES (pH7.4), 150mMNaCl,
10 mM MgCl2, 10 mM glycine, 1 mM DTT, and 10% glycerol at
25 °C. Absorbance at 360 nm was recorded every 3 min for 3 h
using amicroplate reader. The amount of Pi released fromGTP
hydrolysis at each time point was determined by extrapolation
Figure 7. Model of ROC dimer–monomer dynamic equilibrium summa-
rizing our observations that GTP binding to dimeric ROC led to its disso-
ciation intomonomers.GDPbinding, either byGTPhydrolysis or nucleotide
exchange to GDP shifts the equilibrium to the dimeric conformation. The
PD-associated mutations perturbs its GTPase activity and results in a pro-
longed on state.
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using a phosphate standard curve. Data analysis and curve fit-
ting were done with GraphPad Prism 7.
Thermofluor assay
Solutions of 12.5 l of 10 Sypro Orange (prepared from a
5,000 stock concentrate, Molecular Probes) in buffer contain-
ing 30 mM HEPES (pH 7.4), 0.15 M NaCl, 10 mM MgCl2, 10 mM
glycine, 1mMDTT, 4mMGDPorGpp(NH)p, 2M laurylmaltose
neopentyl glycol, and10%glycerol, and12.5l of 25MROCext or
mutants were added to a 96-well thin-wall PCR plate. The plate
washeated in theReal-TimePCRDetectionSystem (Mastercycler
realplex, Eppendorf) from 20 to 85 °C and fluorescence was
recorded in incrementsof 0.4 °C.Theemissionwavelengthwas set
at 550 nm.
Subcellular localization of full-length LRRK2mutants
Mutations in ROC were cloned into 3 FLAG-LRRK2 using
the QuikChange II XL Site-directed Mutagenesis kit (Agilent
Technologies). The resulting plasmids were co-transfected
with 2Myc-RAB29 intoHEK293FT cells using Lipofectamine
2000 (ThermoFisher). Proteins were labeled using primary
antibodies to FLAG (F1804 Sigma, 1:500), myc (MCA1929 Bio-
Rad, 1:500), and TGN46 (AHP500G Bio-Rad, 1:1,000). Alexa
Fluor secondary antibodies donkey anti-mouse 488, donkey
anti-sheep 568, and donkey anti-rat 647 (ThermoFisher) were
used at 1:500. Hoescht 33342 (H3572 ThermoFisher, 1:10,000)
was used as a nuclear dye. Cells were imaged, and overlap of 3
FLAG-LRRK2 with TGN46 was quantified using Cellomics
ArrayScanVTI HCS Reader (Thermo Scientific) and HCS Stu-
dio version 6.6.0.
Author contributions—C.-X. W. and Q. Q. H. formal analysis;
C.-X. W. validation; C.-X. W., J. L., X. R., V. A. E., andN. C. H. inves-
tigation; C.-X. W., Y. P., X. R., Y. T., M. W., and Q. Q. H. methodol-
ogy; C.-X. W. and Q. Q. H. writing-original draft; C.-X. W., J. L.,
Y. P., X. R., S. M. J., M. R. C., and Q. Q. H. writing-review and edit-
ing; J. L., Y. P., X. R., V. A. E., N. C. H., R. S., and Q. Q. H. data cura-
tion; S. M. J., M. W., M. F., R. J. N., andM. R. C. resources; M. F. and
Q. Q. H. funding acquisition; R. J. N., M. R. C., and Q. Q. H. concep-
tualization; Q. Q. H. supervision; Q. Q. H. project administration.
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